

# Single-Dose Liposomal Amphotericin B for Visceral Leish

New England Journal of Medicine

362, 504-512

DOI: [10.1056/nejmoa0903627](https://doi.org/10.1056/nejmoa0903627)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Drug combinations for visceral leishmaniasis. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 595-602.	1.3	53
3	Leishmaniose viscérale traitée par dose unique d'amphotéricine B liposomale. <i>Option/Bio</i> , 2010, 21, 6. 0.0	0.0	0
4	Insecticide-treated bed nets in rural Bangladesh: their potential role in the visceral leishmaniasis elimination programme. <i>Tropical Medicine and International Health</i> , 2010, 15, 1382-1389.	1.0	29
6	Conducting ethical clinical trials for <i>L. donovani</i> in the Bihar region of India. <i>Open Access Journal of Clinical Trials</i> , 0, , 125.	1.5	0
7	Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 83, 357-364.	0.6	43
8	Liposomal amphotericin B and leishmaniasis: Dose and response. <i>Journal of Global Infectious Diseases</i> , 2010, 2, 159.	0.2	152
9	Treatment of visceral leishmaniasis. <i>Journal of Global Infectious Diseases</i> , 2010, 2, 151.	0.2	158
10	Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e818.	1.3	99
11	Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis. <i>Annals of Tropical Medicine and Parasitology</i> , 2010, 104, 535-542.	1.6	31
12	Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. <i>Future Microbiology</i> , 2010, 5, 1301-1303.	1.0	16
13	Current diagnosis and treatment of visceral leishmaniasis. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 919-944.	2.0	79
14	Investigation of plant extracts in traditional medicine of the Brazilian Cerrado against protozoans and yeasts. <i>Journal of Ethnopharmacology</i> , 2010, 131, 116-121.	2.0	40
16	New delivery strategies for the old pentavalent antimonial drugs. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1343-1358.	2.4	69
17	Immunomodulators: use in combined therapy against leishmaniasis. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 739-742.	2.0	29
19	Rare splenic complications and specific serology: decisive diagnostic tools in two cases of visceral leishmaniasis. <i>Italian Journal of Medicine</i> , 2011, 5, 274-277.	0.2	0
20	Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 417-420.	1.1	32
21	Antiparasitic Therapy. <i>Mayo Clinic Proceedings</i> , 2011, 86, 561-583.	1.4	118
22	Targeted killing of <i>Leishmania donovani</i> in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 874-879.	1.3	140

#	ARTICLE	IF	CITATIONS
24	Visceral leishmaniasis: elimination with existing interventions. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 322-325.	4.6	109
25	Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 85, 66-69.	0.6	56
26	Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. <i>Lancet</i> , The, 2011, 377, 477-486.	6.3	281
27	Combination therapy for visceral leishmaniasis. <i>Lancet</i> , The, 2011, 377, 443-444.	6.3	29
28	Paratransgenic Control of Vector Borne Diseases. <i>International Journal of Biological Sciences</i> , 2011, 7, 1334-1344.	2.6	81
29	Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development. <i>Open Medicinal Chemistry Journal</i> , 2011, 5, 31-39.	0.9	79
30	Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India. <i>Journal of Tropical Medicine</i> , 2011, 2011, 1-7.	0.6	43
31	Cutaneous leishmaniasis in a Japanese returnee from West Africa successfully treated with liposomal amphotericin B. <i>Journal of Dermatology</i> , 2011, 38, 1062-1065.	0.6	10
32	Liposomal amphotericin B treatment of cutaneous leishmaniasis due to <i>Leishmania tropica</i> . <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 973-977.	1.3	83
33	Leishmaniasis chemotherapy—challenges and opportunities. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1478-1483.	2.8	353
34	Leishmaniasis impact and treatment access. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1471-1477.	2.8	204
35	Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 66.	0.7	10
36	Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid. <i>Biomaterials</i> , 2011, 32, 8029-8039.	5.7	28
37	Molecular factors governing inhibition of arylimidamides against <i>Leishmania</i> : Conservative computational modeling to improve chemotherapies. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4552-4561.	1.4	14
38	New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas. <i>Drug Development Research</i> , 2011, 72, 451-462.	1.4	3
39	Ambisome plus miltefosine for Indian patients with kala-azar. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2011, 105, 115-117.	0.7	31
40	A Species-Specific Approach to the Use of Non-Antimony Treatments for Cutaneous Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 109-117.	0.6	20
41	Acute Renal Injury as a Result of Liposomal Amphotericin B Treatment in Sodium Stibogluconate Unresponsive Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 85, 1035-1037.	0.6	4

#	ARTICLE	IF	CITATIONS
42	Liposomal Amphotericin B for Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients: 2-Year Treatment Outcomes in Bihar, India. <i>Clinical Infectious Diseases</i> , 2011, 53, e91-e98.	2.9	74
43	Leishmaniasis. <i>Clinical Medicine</i> , 2011, 11, 492-497.	0.8	4
44	Therapy of vector-borne protozoan infections in nonendemic settings. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 583-608.	2.0	3
45	Visceral Leishmaniasis in the Indian Subcontinent: Modelling Epidemiology and Control. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1405.	1.3	142
46	Therapeutic Enhancement of Protective Immunity during Experimental Leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1316.	1.3	8
48	Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 695-702.	1.3	31
49	Antimicrobial Drug-Induced Thrombocytopenia: A Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 818-829.	1.5	31
51	Evaluation of Arylimidamides DB1955 and DB1960 as Candidates against Visceral Leishmaniasis and Chagas' Disease: In Vivo Efficacy, Acute Toxicity, Pharmacokinetics, and Toxicology Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3690-3699.	1.4	24
52	Clinical Challenges in the Management of Leishmania/HIV Coinfection in a Nonendemic Area: A Case Report. <i>Case Reports in Infectious Diseases</i> , 2012, 2012, 1-3.	0.2	3
53	The Economic Value of a Visceral Leishmaniasis Vaccine in Bihar State, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 417-425.	0.6	49
54	Telehealth: a perspective approach for visceral leishmaniasis (kala-azar) control in India. <i>Pathogens and Global Health</i> , 2012, 106, 150-158.	1.0	10
55	Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 839-841.	2.0	2
56	Leishmaniasis in the United States: Treatment in 2012. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 434-440.	0.6	59
57	Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i60-i66.	0.5	71
59	In vitro Antileishmanial Drug Susceptibility of Clinical Isolates from Patients with Indian Visceral Leishmaniasis: Status of Newly Introduced Drugs. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 655-657.	0.6	28
60	Liposomal amphotericin B as a treatment for human leishmaniasis. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 493-510.	1.0	130
61	Management of trypanosomiasis and leishmaniasis. <i>British Medical Bulletin</i> , 2012, 104, 175-196.	2.7	240
62	Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use. <i>Clinical Infectious Diseases</i> , 2012, 55, 543-550.	2.9	247

#	ARTICLE	IF	CITATIONS
63	Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2576-2597.	1.3	605
64	The development and clinical evaluation of second-generation leishmaniasis vaccines. <i>Vaccine</i> , 2012, 30, 134-141.	1.7	94
65	Drug Targeting to Infectious Diseases by Nanoparticles Surface Functionalized with Special Biomolecules. <i>Current Medicinal Chemistry</i> , 2012, 19, 3196-3202.	1.2	46
66	An Oral Formulation of Amphotericin B Attached to Functionalized Carbon Nanotubes Is an Effective Treatment for Experimental Visceral Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2012, 205, 333-336.	1.9	85
67	Antileishmanial bis-arylimidamides: DB766 analogs modified in the linker region and bis-arylimidamide structureâ€“activity relationships. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6806-6810.	1.0	21
68	Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses. <i>Current Fungal Infection Reports</i> , 2012, 6, 349-357.	0.9	3
69	Identification of New Antileishmanial Leads from Hits Obtained by High-Throughput Screening. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1182-1189.	1.4	28
70	Diagnosing visceral leishmaniasis and HIV/AIDS co-infection: a case series study in Pernambuco, Brazil. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2012, 54, 43-47.	0.5	16
71	Rare splenic complications and specific serology: decisive diagnostic tools in two cases of visceral leishmaniasis. <i>Italian Journal of Medicine</i> , 2012, , 274-277.	0.2	0
72	Review of the current treatments for leishmaniasis. <i>Research and Reports in Tropical Medicine</i> , 2012, 3, 69.	2.8	34
73	Lysis syndrome during therapy of visceral leishmaniasis. <i>Infection</i> , 2012, 40, 121-123.	2.3	7
74	3D-QSAR based pharmacophore modeling and virtual screening for identification of novel pteridine reductase inhibitors. <i>Journal of Molecular Modeling</i> , 2012, 18, 1701-1711.	0.8	26
76	Leishmaniasis: new insights from an old and neglected disease. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 109-118.	1.3	94
78	Drug Resistance in Leishmania Parasites. , 2013, , .		13
79	Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 881-895.	1.0	55
81	Antileishmanial Activity, Uptake, and Biodistribution of an Amphotericin B and Poly(L-Glutamic Acid) Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4608-4614.	1.4	18
82	A Targeted and Adjuvanted Nanocarrier Lowers the Effective Dose of Liposomal Amphotericin B and Enhances Adaptive Immunity in Murine Cutaneous Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2013, 208, 1914-1922.	1.9	56
83	Therapeutic Options for Visceral Leishmaniasis. <i>Drugs</i> , 2013, 73, 1863-1888.	4.9	73

#	ARTICLE	IF	CITATIONS
84	Antiprotozoal activity of essential oils derived from <i>Piper</i> spp. grown in Colombia. Journal of Essential Oil Research, 2013, 25, 512-519.	1.3	25
85	Nanotechnological Strategies for the Treatment of Neglected Diseases. Current Pharmaceutical Design, 2013, 19, 7316-7329.	0.9	30
86	Leishmaniasis: an update of current pharmacotherapy. Expert Opinion on Pharmacotherapy, 2013, 14, 53-63.	0.9	207
87	Leishmaniasis: An Update on a Neglected Tropical Disease. , 2013, , 95-138.		3
89	Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects. Expert Review of Anti-Infective Therapy, 2013, 11, 79-98.	2.0	47
90	Preparation and characterisation of amphotericin B-copolymer complex for the treatment of leishmaniasis. Polymer Chemistry, 2013, 4, 584-591.	1.9	8
92	Mechanisms of Miltefosine Resistance in Leishmania. , 2013, , 351-379.		3
93	Visceral Leishmaniasis. , 2013, , 183-198.		2
94	Synthesis and Antiprotozoal Activity of Dicationic <i>m</i> -Terphenyl and 1,3-Dipyridylbenzene Derivatives. Journal of Medicinal Chemistry, 2013, 56, 5473-5494.	2.9	35
95	Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs, 2013, 73, 919-934.	4.9	535
96	Enhanced Brain Delivery of the Opioid Peptide DAMGO in Glutathione PEGylated Liposomes: A Microdialysis Study. Molecular Pharmaceutics, 2013, 10, 1533-1541.	2.3	87
97	Plant-Derived Natural Products for the Treatment of Leishmaniasis. Studies in Natural Products Chemistry, 2013, , 381-429.	0.8	7
98	The therapeutic potential of immune cross-talk in leishmaniasis. Clinical Microbiology and Infection, 2013, 19, 119-130.	2.8	27
99	New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiasis. Current Medicinal Chemistry, 2013, 20, 502-526.	1.2	1
100	Clinical aspects of visceral leishmaniasis in HIV infection. Current Opinion in Infectious Diseases, 2013, 26, 1-9.	1.3	81
101	Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance. Clinical Infectious Diseases, 2013, 56, 1530-1538.	2.9	276
102	Challenges in the Therapy of Visceral Leishmaniasis in Brazil: A Public Health Perspective. Journal of Tropical Medicine, 2013, 2013, 1-5.	0.6	15
103	Human immunodeficiency virus/Leishmania infantum in the first foci of urban American visceral leishmaniasis: clinical presentation from 1994 to 2010. Revista Da Sociedade Brasileira De Medicina Tropical, 2013, 46, 156-160.	0.4	21

#	ARTICLE	IF	CITATIONS
104	Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis. <i>Medical Journal of Australia</i> , 2013, 198, 331-333.	0.8	13
105	New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiasis. <i>Current Medicinal Chemistry</i> , 2013, 20, 502-526.	1.2	27
106	NEWER DRUGS FOR VISCERAL LEISHMANIASIS: A REVIEW. <i>American Journal of Infectious Diseases</i> , 2014, 10, 68-70.	0.1	1
107	Immunity to visceral leishmaniasis: implications for immunotherapy. <i>Future Microbiology</i> , 2014, 9, 901-915.	1.0	41
108	Editorial Commentary: Visceral Leishmaniasis and HIV Coinfection in Bihar, India: A Wake-up Call?. <i>Clinical Infectious Diseases</i> , 2014, 59, 556-558.	2.9	7
109	Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2603.	1.3	52
110	Hypokalaemia-Induced Rhabdomyolysis after Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL) with High-Dose AmBisome in Bangladesh—A Case Report. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2864.	1.3	21
111	Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2536.	1.3	49
112	Species-Directed Therapy for Leishmaniasis in Returning Travellers: A Comprehensive Guide. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2832.	1.3	74
113	Impact of ASHA Training on Active Case Detection of Visceral Leishmaniasis in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2774.	1.3	16
114	Introducing Single Dose Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis in Rural Bangladesh: Feasibility and Acceptance to Patients and Health Staff. <i>Journal of Tropical Medicine</i> , 2014, 2014, 1-7.	0.6	12
115	Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: Current Status and Future Prospects. <i>Frontiers in Immunology</i> , 2014, 5, 296.	2.2	82
116	An overview of visceral leishmaniasis elimination program in India: a picture imperfect. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 929-935.	2.0	12
117	Five-Year Retrospective Italian Multicenter Study of Visceral Leishmaniasis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 414-418.	1.4	16
118	Discovery of the rapanone and suberonone mixture as a motif for leishmanicidal and antifungal applications. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 135-140.	1.4	29
119	Antifungal Drugs. , 2014, , 87-96.		7
120	Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 639-649.	1.3	17
121	Elucidation of Cellular Mechanisms Involved in Experimental Paromomycin Resistance in <i>Leishmania donovani</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2580-2585.	1.4	63

#	ARTICLE	IF	CITATIONS
122	Vaccines to prevent leishmaniasis. <i>Clinical and Translational Immunology</i> , 2014, 3, e13.	1.7	142
123	Crucial CD8+ T-lymphocyte cytotoxic role in amphotericin B nanospheres efficacy against experimental visceral leishmaniasis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e1021-e1030.	1.7	23
124	Biology of Human Pathogenic Trypanosomatids: Epidemiology, Lifecycle and Ultrastructure. <i>Sub-Cellular Biochemistry</i> , 2014, 74, 1-42.	1.0	87
125	Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. <i>Chemical Reviews</i> , 2014, 114, 11305-11347.	23.0	274
126	Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases. <i>Polymer Chemistry</i> , 2014, 5, 1037-1048.	1.9	10
127	Comparison of Point-of-Care Tests for the Rapid Diagnosis of Visceral Leishmaniasis in East African Patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 1109-1115.	0.6	37
128	Non-isoprenoid polyene natural products – structures and synthetic strategies. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 7877-7899.	1.5	33
129	Exploitation of Lectinized Lipo-Polymerosome Encapsulated Amphotericin B to Target Macrophages for Effective Chemotherapy of Visceral Leishmaniasis. <i>Bioconjugate Chemistry</i> , 2014, 25, 1091-1102.	1.8	29
130	Liposomal resiquimod for the treatment of <i>Leishmania donovani</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 168-175.	1.3	37
131	The Emergence of Defined Subunit Vaccines for the Prevention of Leishmaniasis. <i>Current Tropical Medicine Reports</i> , 2014, 1, 154-162.	1.6	6
132	Fruitful Decade for Antileishmanial Compounds from 2002 to Late 2011. <i>Chemical Reviews</i> , 2014, 114, 10369-10428.	23.0	126
133	Covalent Functionalized Self-Assembled Lipo-Polymerosome Bearing Amphotericin B for Better Management of Leishmaniasis and Its Toxicity Evaluation. <i>Molecular Pharmaceutics</i> , 2014, 11, 951-963.	2.3	35
134	Paratransgenic Control of Leishmaniasis: New Developments. , 2014, , 25-43.		4
135	Pathogenesis of Leishmaniasis. , 2014, , .		2
136	Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis. <i>The Lancet Global Health</i> , 2014, 2, e7-e8.	2.9	12
137	Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. <i>The Lancet Global Health</i> , 2014, 2, e51-e57.	2.9	58
138	Co-infection of visceral leishmaniasis and HIV-1: a surviving case in China and review of treatment strategies. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-5.	3.0	2
139	Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan. <i>Tropical Medicine and International Health</i> , 2015, 20, 1674-1684.	1.0	30



#	ARTICLE	IF	CITATIONS
140	Plenary Sessions. <i>Tropical Medicine and International Health</i> , 2015, 20, 1-147.	1.0	5
142	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 276.	0.7	22
143	Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. <i>The Cochrane Library</i> , 2015, 2015, CD010481.	1.5	45
145	Visceral Leishmaniasis as a Possible Reason for Pancytopenia. <i>Frontiers in Pediatrics</i> , 2015, 3, 59.	0.9	16
146	Sequential Chemoimmunotherapy of Experimental Visceral Leishmaniasis Using a Single Low Dose of Liposomal Amphotericin B and a Novel DNA Vaccine Candidate. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5819-5823.	1.4	35
147	Drugs for Protozoal Infections Other Than Malaria. , 2015, , 510-518.e3.		4
148	Miltefosine, an FDA-approved drug for the "orphan disease"™, leishmaniasis. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 727-735.	0.5	12
149	Cutaneous and mucocutaneous leishmaniasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 911-926.	0.6	143
150	Liposomal systems as carriers for bioactive compounds. <i>Biophysical Reviews</i> , 2015, 7, 391-397.	1.5	37
151	Hematological toxicities associated with amphotericin B formulations. <i>Leukemia and Lymphoma</i> , 2015, 56, 2889-2894.	0.6	22
152	SAR refinement of antileishmanial N2,N4-disubstituted quinazoline-2,4-diamines. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5182-5189.	1.4	26
153	A Novel Molecular Test to Diagnose Canine Visceral Leishmaniasis at the Point of Care. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 970-975.	0.6	27
154	Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003699.	1.3	24
155	Targeting Ergosterol Biosynthesis in <i>Leishmania donovani</i> : Essentiality of Sterol 14 $\alpha$ -demethylase. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003588.	1.3	90
156	Antileishmanial drug discovery: comprehensive review of the last 10 years. <i>RSC Advances</i> , 2015, 5, 32376-32415.	1.7	126
157	Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 471-473.	0.6	22
158	Rapidly fatal reactive hemophagocytosis syndrome associated with visceral leishmaniasis. <i>Journal of Pediatric Infectious Diseases</i> , 2015, 06, 269-271.	0.1	3
159	Single-Dose Indigenous Liposomal Amphotericin B in the Treatment of Indian Visceral Leishmaniasis: A Phase 2 Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 513-517.	0.6	41

#	ARTICLE	IF	CITATIONS
160	New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape. <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 247-260.	2.4	31
161	Drug resistance analysis by next generation sequencing in <i>Leishmania</i> . <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2015, 5, 26-35.	1.4	66
162	Investigational drugs for visceral leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 43-59.	1.9	44
163	Atypical presentation in adults in the largest community outbreak of leishmaniasis in Europe (Fuenlabrada, Spain). <i>Clinical Microbiology and Infection</i> , 2015, 21, 269-273.	2.8	31
164	An update on pharmacotherapy for leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 237-252.	0.9	213
165	Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004415.	1.3	33
166	Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review. <i>African Journal of Pharmacy and Pharmacology</i> , 2016, 10, 512-520.	0.2	2
167	The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2016, 110, 321-323.	0.7	7
168	The immunology of post-kala-azar dermal leishmaniasis (PKDL). <i>Parasites and Vectors</i> , 2016, 9, 464.	1.0	93
170	Combination Therapy for Leishmaniases. , 2016, , 79-88.		0
171	Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models. <i>Parasites and Vectors</i> , 2016, 9, 24.	1.0	47
172	Antimicrobial Agents for Ocular Use: Bacterial, Fungal, Viral, and Protozoal Infections. , 2016, , 285-332.		2
173	Elimination of visceral leishmaniasis on the Indian subcontinent. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e304-e309.	4.6	98
174	Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia. <i>BMC Infectious Diseases</i> , 2016, 16, 548.	1.3	27
175	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>Clinical Infectious Diseases</i> , 2016, 63, e202-e264.	2.9	235
176	Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis. <i>Vaccine</i> , 2016, 34, 2779-2786.	1.7	35
177	Recent developments and future prospects in the treatment of visceral leishmaniasis. <i>Therapeutic Advances in Infectious Disease</i> , 2016, 3, 98-109.	1.1	99
178	Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. <i>Infectious Diseases of Poverty</i> , 2016, 5, 19.	1.5	137

#	ARTICLE	IF	CITATIONS
179	Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis. <i>Journal of Parasitic Diseases</i> , 2016, 40, 475-484.	0.4	13
180	Treatment of visceral leishmaniasis: options and choice. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 142-143.	4.6	15
181	Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes. <i>European Journal of Medicinal Chemistry</i> , 2016, 110, 237-245.	2.6	19
182	Comparison between liposomal formulations of amphotericin B. <i>Medical Mycology</i> , 2016, 54, 223-231.	0.3	75
183	Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. <i>Drugs</i> , 2016, 76, 485-500.	4.9	332
184	Pharmacology of Ocular Therapeutics. , 2016, , .		6
185	Visceral leishmaniasis: a forgotten epidemic. <i>Archives of Disease in Childhood</i> , 2016, 101, 561-567.	1.0	22
186	Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries. <i>Acta Tropica</i> , 2016, 155, 113-123.	0.9	79
187	Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome®). <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 93-98.	0.6	13
188	Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. <i>Clinical Drug Investigation</i> , 2017, 37, 259-272.	1.1	47
189	Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats. <i>Drug Delivery</i> , 2017, 24, 40-50.	2.5	83
190	Short-course Regimens of Liposomal Amphotericin B for the Treatment of Mediterranean Visceral Leishmaniasis in Children. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 849-854.	1.1	10
191	Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	23
192	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 24-45.	0.6	191
193	Cost-effectiveness of liposomal amphotericin B in hospitalised patients with mucocutaneous leishmaniasis. <i>Tropical Medicine and International Health</i> , 2017, 22, 1569-1578.	1.0	9
194	The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome®). <i>Journal of Liposome Research</i> , 2017, 27, 173-179.	1.5	21
196	Prevalence, severity, and pathogenesis of anemia in visceral leishmaniasis. <i>Parasitology Research</i> , 2017, 116, 457-464.	0.6	31
197	Antiparasitic Agents. , 2017, , 1345-1372.e2.		15

#	ARTICLE	IF	CITATIONS
198	Alternative to Chemotherapyâ€”The Unmet Demand against Leishmaniasis. <i>Frontiers in Immunology</i> , 2017, 8, 1779.	2.2	34
199	<i>Platonia insignis</i> Mart., a Brazilian Amazonian Plant: The Stem Barks Extract and Its Main Constituent Lupeol Exert Antileishmanial Effects Involving Macrophages Activation. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-12.	0.5	13
200	Nanostructures for Improved Antimonial Therapy of Leishmaniasis. , 2017, , 419-437.		2
201	Nanostructured delivery systems with improved leishmanicidal activity: a critical review. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 5289-5311.	3.3	83
202	Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006052.	1.3	571
203	Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in <i>Leishmania infantum</i> . <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005620.	1.3	28
204	Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1006-1012.	1.1	17
205	The therapeutic strategies against <i>Naegleria fowleri</i> . <i>Experimental Parasitology</i> , 2018, 187, 1-11.	0.5	43
206	Emerging role of amiodarone and dronedarone, as antiarrhythmic drugs, in treatment of leishmaniasis. <i>Acta Tropica</i> , 2018, 185, 34-41.	0.9	10
207	Molecular diagnosis of protozoan parasites by Recombinase Polymerase Amplification. <i>Acta Tropica</i> , 2018, 182, 4-11.	0.9	28
208	Antiparasitic Agents. , 2018, , 1567-1587.e2.		6
209	Parasitic and Protozoal Infections. , 2018, , 271-294.		0
210	Treatment of Visceral Leishmaniasis. , 2018, , 169-190.		1
211	Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies. <i>Clinical Microbiology and Infection</i> , 2018, 24, 591-598.	2.8	19
212	Visceral Leishmaniasisâ€”Optimum Treatment Options in Children. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 492-494.	1.1	18
213	The Leishmaniases: Old Neglected Tropical Diseases. , 2018, , .		35
214	Monitoring of Parasite Kinetics in Indian Postâ€”Kala-azar Dermal Leishmaniasis. <i>Clinical Infectious Diseases</i> , 2018, 66, 404-410.	2.9	52
215	Understanding serine proteases implications on <i>Leishmania</i> spp lifecycle. <i>Experimental Parasitology</i> , 2018, 184, 67-81.	0.5	24

#	ARTICLE	IF	CITATIONS
216	Chemotherapeutics of visceral leishmaniasis: present and future developments. <i>Parasitology</i> , 2018, 145, 481-489.	0.7	90
217	Phagocytes and the Leishmania Parasite: A Marriage of Convenience. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2018, 54, 231-244.	0.2	0
218	AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> , 2018, 19, 649.	0.7	41
219	Leishmaniasis cutánea y embarazo. <i>Biomedica</i> , 2018, 38, 8-12.	0.3	0
220	Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006830.	1.3	17
221	SB-83, a 2-Amino-thiophene derivative orally bioavailable candidate for the leishmaniasis treatment. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1670-1678.	2.5	5
222	Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	5.7	145
223	Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. <i>Infectious Diseases of Poverty</i> , 2018, 7, 80.	1.5	9
224	Epidemiological and clinical features of visceral leishmaniasis in children in Alicante Province, Spain. <i>Paediatrics and International Child Health</i> , 2018, 38, 1-6.	0.3	4
225	Accelerated Blood Clearance (ABC) Phenomenon Favors the Accumulation of Tartar Emetic in Pegylated Liposomes in BALB/c Mice Liver. <i>Pathology Research International</i> , 2018, 2018, 1-7.	1.4	8
226	Visceral leishmaniasis in an infant gorilla ( <i>Gorilla gorilla gorilla</i> ): Clinical signs, diagnosis, and successful treatment with single-dose liposomal amphotericin B. <i>Journal of Medical Primatology</i> , 2018, 47, 416-418.	0.3	6
227	Drug Resistance in Leishmania Parasites. , 2018, , .		3
228	Visceral Leishmaniasis. , 2018, , 159-176.		3
229	Leishmaniasis. <i>Lancet, The</i> , 2018, 392, 951-970.	6.3	1,264
230	Promising nanotherapy in treating leishmaniasis. <i>International Journal of Pharmaceutics</i> , 2018, 547, 421-431.	2.6	59
231	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 393-401.	2.9	62
232	Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007653.	1.3	20
233	Recent advances in amphotericin B delivery strategies for the treatment of leishmaniasis. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 1063-1079.	2.4	43

#	ARTICLE	IF	CITATIONS
234	&lt;p&gt;Synthesis, characterization, and mechanistic studies of a gold nanoparticle&acirc&quot; amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity&lt;/p&gt;. International Journal of Nanomedicine, 2019, Volume 14, 6073-6101.	3.3	45
235	Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. Nanomedicine, 2019, 14, 1911-1927.	1.7	27
236	Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 70-79.	1.4	22
237	Topoisomerase IB poisons induce histone H2A phosphorylation as a response to DNA damage in Leishmania infantum. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 39-48.	1.4	6
238	Visceral Leishmaniasis. Infectious Disease Clinics of North America, 2019, 33, 79-99.	1.9	99
239	Genomic instability at the locus of sterol C24-methyltransferase promotes amphotericin B resistance in Leishmania parasites. PLoS Neglected Tropical Diseases, 2019, 13, e0007052.	1.3	39
240	Current and promising novel drug candidates against visceral leishmaniasis. Pure and Applied Chemistry, 2019, 91, 1385-1404.	0.9	29
241	Isolated Laryngeal Leishmaniasis: A Diagnostic Dilemma. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, 71, 872-875.	0.3	0
242	Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 595-612.	1.5	3
243	Current and emerging medications for the treatment of leishmaniasis. Expert Opinion on Pharmacotherapy, 2019, 20, 1251-1265.	0.9	114
244	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clinical Infectious Diseases, 2019, 68, S244-S259.	2.9	40
245	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical Infectious Diseases, 2019, 68, S260-S274.	2.9	73
246	Leishmaniasis control: limitations of current drugs and prospects of natural products. , 2019, , 293-350.		4
247	Walking a tightrope: drug discovery in visceral leishmaniasis. Drug Discovery Today, 2019, 24, 1209-1216.	3.2	33
248	Assessment of quality of life using WHOQOL-BREF in patients with visceral leishmaniasis. Health and Quality of Life Outcomes, 2019, 17, 53.	1.0	10
250	Targeted nanoparticles for treating infectious diseases. , 2019, , 169-185.		1
251	Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges. Nanomaterials, 2019, 9, 1749.	1.9	63
252	Leishmaniasis: treatment, drug resistance and emerging therapies. Expert Opinion on Orphan Drugs, 2019, 7, 1-10.	0.5	38

#	ARTICLE	IF	CITATIONS
254	Stigmasterol as a potential biomarker for amphotericin B resistance in <i>Leishmania donovani</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 942-950.	1.3	11
255	The role of liposomes in clinical nanomedicine development. What now? Now what?. <i>Journal of Controlled Release</i> , 2020, 318, 256-263.	4.8	226
256	Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections. <i>Molecules</i> , 2020, 25, 5075.	1.7	18
257	HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies. <i>Current Treatment Options in Infectious Diseases</i> , 2020, 12, 422-437.	0.8	2
258	Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?. <i>Microorganisms</i> , 2020, 8, 1069.	1.6	16
259	Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An in vitro and Preclinical Study. <i>Frontiers in Chemistry</i> , 2020, 8, 510.	1.8	18
260	Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. <i>Cell Reports</i> , 2020, 30, 2512-2525.e9.	2.9	34
261	Repurposing of Drugs Is a Viable Approach to Develop Therapeutic Strategies against Central Nervous System Related Pathogenic Amoebae. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2378-2384.	1.7	8
262	Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria. <i>Marine Drugs</i> , 2020, 18, 187.	2.2	32
263	The advantages of nanomedicine in the treatment of visceral leishmaniasis: between sound arguments and wishful thinking. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 471-487.	2.4	2
264	Chemogenomics and bioinformatics approaches for prioritizing kinases as drug targets for neglected tropical diseases. <i>Advances in Protein Chemistry and Structural Biology</i> , 2021, 124, 187-223.	1.0	2
265	A mushroom derived "carbohydrate" fraction™ reinstates host immunity and protects from <i>Leishmania donovani</i> infection. <i>Parasite Immunology</i> , 2021, 43, e12806.	0.7	2
266	Trendings of amphotericin B-loaded nanoparticles as valuable chemotherapeutic approaches against leishmaniasis. , 2021, , 291-327.		2
267	Drug resistance and repurposing of existing drugs in Leishmaniasis. , 2021, , 103-124.		3
268	Modern Drug Discovery and Development in the Area of Leishmaniasis. , 2021, , 123-158.		3
269	The global procurement landscape of leishmaniasis medicines. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009181.	1.3	23
270	Quo vadis? Central Rules of Pathogen and Disease Tropism. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 640987.	1.8	6
271	Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009013.	1.3	4

#	ARTICLE	IF	CITATIONS
272	Efficacy and safety of single-dose liposomal amphotericin B in patients with visceral leishmaniasis in Bangladesh: a real-life experience. <i>Journal of Parasitic Diseases</i> , 2021, 45, 903-911.	0.4	6
273	Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 88, 201-206.	0.2	4
275	Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral. <i>Revista Iberoamericana De Micología</i> , 2021, 38, 101-104.	0.4	3
276	Self-assembled ultrasmall silver nanoclusters on liposome for topical antimicrobial delivery. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 200, 111618.	2.5	12
277	In Vitro Susceptibility to Miltefosine of <i>Leishmania infantum</i> (syn. <i>L.Âchagasi</i> ) Isolates from Different Geographical Areas in Brazil. <i>Microorganisms</i> , 2021, 9, 1228.	1.6	9
278	How urgent is the need for new antifungals?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1857-1870.	0.9	18
279	Well-Tolerated Amphotericin B Derivatives That Effectively Treat Visceral Leishmaniasis. <i>ACS Infectious Diseases</i> , 2021, 7, 2472-2482.	1.8	3
280	Exploring Innovative Leishmaniasis Treatment: Drug Targets from Preâ€Clinical to Clinical Findings. <i>Chemistry and Biodiversity</i> , 2021, 18, e2100336.	1.0	10
281	Leishmaniasis: Challenges in the Control and Eradication. , 2013, , 247-264.		2
282	A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance. , 2011, , 35-46.		2
283	<i>Leishmania</i> Species (Leishmaniasis). , 2012, , 1285-1291.e2.		3
284	Antiparasitic Agents. , 2012, , 1518-1545.e3.		5
285	I. Appraisal of Leishmaniasis Chemotherapy, Current Status and Pipeline StrategiesChapter 1. Leishmaniasis, Impact and Therapeutic Needs. <i>RSC Drug Discovery Series</i> , 2017, , 1-23.	0.2	8
286	Plasticity of the <i>Leishmania</i> genome leading to gene copy number variations and drug resistance. <i>F1000Research</i> , 2016, 5, 2350.	0.8	111
287	Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005635.	1.3	57
288	Sterol 14 $\beta$ -demethylase mutation leads to amphotericin B resistance in <i>Leishmania mexicana</i> . <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005649.	1.3	43
289	Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005706.	1.3	43
290	Towards elimination of visceral leishmaniasis in the Indian subcontinentâ€”Translating research to practice to public health. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005889.	1.3	53



#	ARTICLE	IF	CITATIONS
291	Identification and Characterization of the Regions Involved in the Nuclear Translocation of the Heterodimeric Leishmanial DNA Topoisomerase IB. PLoS ONE, 2013, 8, e73565.	1.1	10
292	Association of Liposome-Encapsulated Trivalent Antimonial with Ascorbic Acid: An Effective and Safe Strategy in the Treatment of Experimental Visceral Leishmaniasis. PLoS ONE, 2014, 9, e104055.	1.1	14
293	In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases. Current Medicinal Chemistry, 2019, 26, 4355-4379.	1.2	24
294	Outwitting an Old Neglected Nemesis: A Review on Leveraging Integrated Data-Driven Approaches to Aid in Unraveling of Leishmanicides of Therapeutic Potential. Current Topics in Medicinal Chemistry, 2020, 20, 349-366.	1.0	13
295	Visceral leishmaniasis. Tropical Parasitology, 2015, 5, 83.	0.2	17
296	Advances in the Diagnosis of Visceral Leishmaniasis. Journal of Molecular Biomarkers & Diagnosis, 2013, 4, .	0.4	2
297	Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field. Journal of Tropical Diseases, 2016, 04, .	0.1	3
298	Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1498-1502.	0.6	9
299	Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar. American Journal of Tropical Medicine and Hygiene, 2019, 101, 795-798.	0.6	11
300	Liposomal Amphotericin B Treatment and the Leishmaniases. American Journal of Tropical Medicine and Hygiene, 2019, 101, 727-728.	0.6	7
301	Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment. Annals of Saudi Medicine, 2014, 34, 143-146.	0.5	8
302	Leishmaniasis: A forgotten disease among neglected people. The Internet Journal of Health, 2010, 11, .	0.0	2
305	Combination Therapy for Leishmaniases. , 2011, , 47-56.		0
307	Chapter 6. Drugs for Kinetoplastid Diseases “ Current Situation and Challenges. RSC Drug Discovery Series, 2011, , 134-158.	0.2	0
310	Liposomal Amphotericin B Usefulness in Critical Care Unit: A Review Study. Archives of Critical Care Medicine, 2016, 2, .	0.0	0
311	A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance. , 2016, , 53-66.		1
312	Drug Safety Monitoring for Liposomal Amphotericin B. , 2016, , 249-255.		0
313	Liposomal Amphotericin B Usefulness in Critical Care Unit: A Review Study. Archives of Critical Care Medicine, 2016, 2, .	0.0	0

#	ARTICLE	IF	CITATIONS
314	Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis. , 2016, , 297-306.		0
315	Drug Resistance in Leishmaniasis. , 2017, , 1293-1304.		0
316	DNA Topoisomerases as Promising Targets for <i>Leishmania</i> Chemotherapy. RSC Drug Discovery Series, 2017, , 348-370.	0.2	0
317	Rising visceral leishmaniasis in Holy Himalayas (Uttarakhand, India) – A cross-sectional hospital-based study. Journal of Family Medicine and Primary Care, 2020, 9, 1362.	0.3	3
318	Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis. Current Research in Immunology, 2021, 2, 194-201.	1.2	2
319	Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome™) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy. American Journal of Tropical Medicine and Hygiene, 2020, 103, 308-314.	0.6	10
320	A rare etiology of preseptal cellulitis: Leishmaniasis. Journal Francais D'Ophtalmologie, 2020, 43, e247-e249.	0.2	1
322	Assay development in leishmaniasis drug discovery: a comprehensive review. Expert Opinion on Drug Discovery, 2022, 17, 151-166.	2.5	7
323	A profile of research on the parasitic trypanosomatids and the diseases they cause. PLoS Neglected Tropical Diseases, 2022, 16, e0010040.	1.3	22
324	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. New England Journal of Medicine, 2022, 386, 1109-1120.	13.9	119
325	Molecular Informatics of Trypanothione Reductase of <i>Leishmania major</i> Reveals Novel Chromen-2-One Analogues as Potential Leishmanicides. , 0, , .		0
326	Combination Therapy for HIV-Associated Cryptococcal Meningitis – A Success Story. Journal of Fungi (Basel, Switzerland), 2021, 7, 1098.	1.5	3
327	Roadmap of pre-clinical treatment for Visceral Leishmaniasis. Drug Development Research, 2022, 83, 317-327.	1.4	7
332	Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes. Pharmaceutics, 2022, 14, 989.	2.0	14
333	Sinonasal mucormycosis and liposomal amphotericin B: A quest for dose optimization.. Indian Journal of Pharmacology, 2022, 54, 90-96.	0.4	0
335	Amphotericin B: A drug of choice for Visceral Leishmaniasis. Acta Tropica, 2022, 235, 106661.	0.9	23
336	Visceral leishmaniasis elimination in India: progress and the road ahead. Expert Review of Anti-Infective Therapy, 2022, 20, 1381-1388.	2.0	7
337	Efficacy and safety of pharmacotherapeutic interventions used in visceral leishmaniasis clinical trials: A systematic review and network meta-analysis. Asian Pacific Journal of Tropical Medicine, 2022, 15, 343.	0.4	0

#	ARTICLE	IF	CITATIONS
338	Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics. <i>Microorganisms</i> , 2022, 10, 1887.	1.6	30
339	Mechanistic insight into the role of mevalonate kinase by a natural fatty acid-mediated killing of <i>Leishmania donovani</i> . <i>Scientific Reports</i> , 2022, 12, .	1.6	2
340	How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings?. <i>Clinical Infectious Diseases</i> , 2023, 76, 944-949.	2.9	5
341	The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: Findings from a qualitative methods study of participants and researchers in Botswana and Uganda. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010825.	1.3	5
342	Micro and nanotechnologies: The little formulations that could. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	9
343	Antiparasitic Agents. , 2023, , 1598-1617.e2.		1
344	Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 276-283.	1.3	1
345	Amphotericin B Nano-Assemblies Circumvent Intrinsic Toxicity and Ensure Superior Protection in Experimental Visceral Leishmaniasis with Feeble Toxic Manifestation. <i>Vaccines</i> , 2023, 11, 100.	2.1	2
346	The paradigm of intracellular parasite survival and drug resistance in leishmanial parasite through genome plasticity and epigenetics: Perception and future perspective. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	0
347	Dosing implications for liposomal amphotericin B in pregnancy. <i>Pharmacotherapy</i> , 2023, 43, 452-462.	1.2	1
348	Visceral and Tegumentary Leishmaniasis. , 2023, , 235-261.		0
349	Parasitic and Protozoal Infections. , 2023, , 339-360.		0
350	Antifungal Drugs. , 2021, , 127-139.		0
351	Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates. <i>Biomolecules</i> , 2023, 13, 637.	1.8	4
352	The management of <i>Babesia</i> , amoeba and other zoonotic diseases provoked by protozoa. <i>Expert Opinion on Therapeutic Patents</i> , 2023, 33, 179-192.	2.4	1
356	Drug delivery and functional nanoparticles. , 2023, , 447-484.		0
358	Epidemiology of Visceral Leishmaniasis in India. , 0, , .		0
360	Current Challenges and Nanotechnology-Based Pharmaceutical Approaches for the Treatment and Control of Visceral Leishmaniasis. , 2023, , 479-498.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------